Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: A recurrent events analysis

Journal of Infectious Diseases

Volumn 205, Issue 8, 2012, Pages 1230-1238

  Grennan, J Troy ^a   Loutfy, Mona R ^b,c   Su, Desheng ^d   Harrigan, P Richard ^e,f   Cooper, Curtis ^g   Klein, Marina ^h,i   MacHouf, Nima ^j   Montaner, Julio S G ^e,f   Rourke, Sean ^b,k,l   Tsoukas, Christos ⁱ   Hogg, Bob ^e,m   Raboud, Janet ^b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j Clinique Medical l'Actuel   (Canada)

^k ST MICHAEL'S HOSPITAL   (Canada)

^l ONTARIO HIV TREATMENT NETWORK   (Canada)

^m SIMON FRASER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HAZARD RATIO; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REBOUND; RECURRENT INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIROLOGIC BLIP; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; RNA, VIRAL; VIRAL LOAD;

EID: 84859029700     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis104     Document Type: Article

References (35)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998; 338:853-60.
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS SocietydUSA Panel. J Am Med Assoc 2006; 296:827-43.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department ofHealth and Human Services, 2011: 1-166. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 5 May 2011.
4. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS SocietydUSA panel. J Am Med Assoc 2010; 304:321-33.
5. Mira JA, Macias J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002; 7:251-6.
6. Greub G, Cozzi-Lepri A, Lederberger B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-9.
7. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS 2002; 16:2035-41.
8. DiMascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77:12165-72.
9. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280:1866-7.
10. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-28.
11. Nettles RE, Kieffer TL. Update on HIV-1 viral load blips. Curr Opin HIV AIDS 2006; 1:157-61.
12. Stosor V, Palella FJ, Berzins B, et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infec Dis 2005; 41:1671-4.
13. Smit E, Bhattacharya S, Osman H, Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Amplicor to Cobas Taqman Assay. J Acquir Immune Defic Syndr 2009; 51:364-5.
14. Lima V, Harrigan R, Montaner JSG. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
15. Brambilla D, Granger S, Bremer J. Variations in HIV RNA assays at low RNA concentration [abstract 774]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA). Alexandria, VA: CROI, 2000.
16. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-9.
17. Raboud JM, Rae S, Woods R, Harris M, Montaner JSG. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002; 16:1627-32.
18. Martinez V, Marcelin AG, Morini JP, et al. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitorbased regimen. AIDS 2005; 19:1065-9.
19. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41:1326-32.
20. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196:1773-8.
21. Garcia-Gasco P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61:699-704.
22. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to ,400 copies/mL. AIDS 2002; 16:1521-7.
23. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16:615-8.
24. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol 2005; 33:75-8.
25. Harrigan R, Sherlock C, Hogg R, et al. What should be the primary virological endpoint in clinical trials of ARV efficacy? [Paper 661]. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: CROI, 2011.
26. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28:105-13.
27. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 2005; 51:195-200.
28. Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV- 1-infected patients experiencing persistent low-level viremia during first line therapy. J Infect Dis 2011; 204:515-20.
29. Flandre P, Pincon C, Aboulker JP, et al. Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials. HIV Clin Trials 2006; 7:116-24.
30. Srasuebkul P, Ungsedhapand C, Ruxrungtham K, et al. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIVMed 2007; 8:46-54.
31. Palmer AK, Klein MB, Raboud J, et al. The CANOC Collaboration. Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol 2011; 40:25-32.
32. Percus JK, Percus OE, Markowitz M, et al. The distribution of viral blips observed in HIV-1-infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003; 65:263-77.
33. DiMascio M, Ribeiro RM, Markowitz M, et al. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci 2004; 188:47-62.
34. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981; 68:373-9.
35. Miller LG, Golin CE, Liu H, et al. No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis 2004; 189:1487-96.